²é¿´: 2773  |  »Ø¸´: 7
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

mouse103

ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)

[½»Á÷] Å·ÖÞÒ©µä¶ÔÔ­ÁÏÒ©ÖлÇËáõ¥Àà»ùÒòÔÓÖʵÄÎå¸öÐÂͨÔò ÒÑÓÐ6È˲ÎÓë

ÒÔÏÂÊÇÅ·ÖÞÒ©µä¶ÔÔ­ÁÏÒ©ÖлùÒòÔÓÖʵÄÎå¸öÐÂͨÔò£¬Í¨¹ýÖÐÎÄ·­Òë·ÖÏí¸ø³æÓÑ£¬ÈçÓв»µ±»¶Ó­Ö¸Õý¡£Í¬Ê±Ï£ÍûÄÄλ³æÓÑÄÜ·ÖÏíEP8.7ÖиÃÄÚÈݵÄÎå¸ö׍ָ¡£ÆÚ´ý£¡
                                                         Å·ÖÞÒ©µä¶ÔÔ­ÁÏÒ©ÖлùÒòÔÓÖʵÄÎå¸öÐÂͨÔò
£¨Five new General Chapters in the European Pharmacopoeia on Genotoxic Impurities in Pharmaceutical APIs£©
»ÇËá¾­³£ÓÃÓÚÔ­ÁÏÒ©µÄÉú²úÖС£»ÇËá¿ÉÄÜÓÃÔÚ³ÉÑιý³Ì£¬Ô­ÁÏÒ©ºÏ³ÉÖл»ùÍÅ»òËá´ß»¯¡£¹¤ÒÕÖÐÈç¹ûÓõ½¶ÌÁ´´¼£¬Èç¼×´¼¡¢ÒÒ´¼»òÒì±û´¼£¬Ôò¿ÉÄÜ»áºÍ»ÇËáÉú³É»ÇËáõ¥¡£ËüÃÇ¿ÉÄÜÓÐDZÔÚ»ùÒò¶¾ÐÔ£¨DNAÍé»ù»¯£©¡£
Sulfonic acids are often used for the manufacture of pharmaceutical APIs. They serve as counterions in crystallisation processes, as protective groups or acid catalysts in API syntheses. Here, if short-chain alcohols such as methanol, ethanol or isopropanol are present, the formation of esters of these sulfonic acids can occur, which may have a genotoxic potential (alkylation of DNA).
2008ÄêÅ·ÃËÒ©µäίԱ»á³ÉÁ¢Á˼׻ÇËáÑι¤×÷×飬ÄⶨÁË5¸ö²»Í¬»ÇËáÎïµÄͨÔò£¬ÕâЩͨÔòÔÚEPÔö²¹8.7Öй«²¼£¬½«×Ô2016Äê4ÔÂ1ÈÕ¿ªÊ¼ÉúЧ¡£Í¨Ôò±êÌâÈçÏ£º
The Mesilate Working Party which has been appointed in 2008 by the European Pharmacopoeia Commission has elaborated five General Chapters on different sulfonates which have been published in the European Pharmacopoeia Supplement 8.7 that came into force on 1 April 2016. The General Chapters are as follows:
2.5.37¼×»ÇËáÖеļ׻ù¡¢ÒÒ»ùºÍÒì±û»ù¼×»ÇËáõ¥£¨Methyl, ethyl and isopropyl methanesulfonate in methanesulfonic acid£©
2.5.38Ô­ÁÏÒ©Öеļ׻ù¡¢ÒÒ»ùºÍÒì±û»ù¼×»ÇËáõ¥£¨Methyl, ethyl and isopropyl methanesulfonate in active substances£©
2.5.39¼×»ÇËáÖеļ׻Çõ£ÂÈ£¨Methanesulfonyl chloride in methanesulfonic acid£©
2.5.40Ô­ÁÏÒ©Öеļ׻ù¡¢ÒÒ»ùºÍÒì±û»ù¼×±½»ÇËáõ¥£¨Methyl, ethyl and isopropyl toluenesulfonate in active substances£©
2.5.41Ô­ÁÏÒ©Öеļ׻ù¡¢ÒÒ»ùºÍÒì±û»ù±½»ÇËáõ¥£¨Methyl, ethyl and isopropyl benzenesulfonate in active substances£©
2016Äê2ÔÂ25ÈÕEDQM±¨µÀ£¬Å·ÃËÒ©µäίԱ»á¼×»ÇËáÑι¤×÷×éÍê³É2.5.41Õ£¬±êÖ¾×Ź¤×÷×éµÄ¹¤×÷½áÊø¡£Í¬Ê±£¬Î¯Ô±»á»¹¾ö¶¨ÐÞ¶©Ô­ÁÏÒ©-»ÇËáÑθ÷ÂÛÖеġ±Éú²ú¡°²¿·Ö£¬²ÉÓÃÁíÒ»·Ý±ê×¼ÎļþÀ´Ìæ´ú¡£¸ù¾Ý´Ë±ê×¼Îļþ£¬ÔÚÔ­ÁÏÒ©Éú²úÖжԻùÒò¶¾ÐÔÔÓÖÊÓ¦½øÐзçÏÕ¹ÜÀí¡£Îı¾ÈçÏ£º
As reported in a press release from the EDQM dated 25 February 2016 the completion of Chapter 2.5.41 marks the end of the Mesilate Working Party, as decided by the Ph. Eur. Commission. Simultaneously, the Commission had also decided to revise the section "Production" in APIs-Sulfonates monographs and replace it by an additional standard text according to which the principles of risk management have to be used in the manufacture of APIs with regard to the genotoxic impurities. The text is as follows:
¡°¡¾xxxõ¥¡¿¾ßÓлùÒò¶¾ÐÔ£¬¶øÇÒÊÇ¡¾xxÔ­ÁÏÒ©¡¿µÄDZÔÚÔÓÖÊ¡£Éú²ú¹ý³ÌÖÐÓ¦¿¼ÂÇÖÊÁ¿·çÏÕ¹ÜÀíÔ­Ôò£¬Í¬Ê±¿¼ÂÇÆðʼÎïÁÏ¡¢¹¤ÒÕÄÜÁ¦ºÍÑéÖ¤¡£Í¨Ôò¡¾2.5.XX¡¿¿ÉÒÔÓÃÀ´°ïÖúÉú²úÉÌ¡£¡±
¡°It is considered that [XXX esters] are genotoxic and are potential impurities in [name of the API]. The manufacturing process should be developed taking into consideration the principles of quality risk management, together with considerations of the quality of starting materials, process capability and validation. The general method [2.5.XX] is available to assist manufacturers."
EPͨÔòÒ»°ãÀ´ËµÖ»Óе±ËüÃÇÔÚ¸÷ÂÛÖб»ÒýÓÃʱ¾ßÓÐÔ¼ÊøÁ¦£¬Î¨Ò»µÄÀýÍâÊǵ±Ö»ÊÇ×÷Ϊ²Î¿¼Ê±Îª½¨Òé¡£ÕâÊÊÓÃÓÚÉÏÊöÎå¸öͨÔò¡£ÔÚ¡°Éú²ú¡±²¿·ÖµÄÐÂÎļþÄÚÈÝ£¬Ä¿µÄÊǾ¯Ê¾ÉÏÊÐÐí¿ÉµÄÉêÇëÈË´ËÀà»ÇËáÔÓÖÊÏà¹ØµÄ·çÏÕ¡£²¢Ã»ÓÐÇ¿ÖÆÉ걨ÈËʵʩͨÔòÖÐËùÊöµÄ·ÖÎö²âÊÔ£¬µ«ÐèÒªÔÚÉ걨ÎļþÖвÉÓ÷çÏÕÆÀ¹ÀµÄ·½Ê½³ä·ÖÂÛÖ¤ÕâЩÔÓÖʲ»»á´æÔÚ¡£×îÖÕ¾ö¶¨ÕâЩÂÛÖ¤ÊÇ·ñ³ä·ÖÊÇÒ©¼àµ±¾ÖµÄÆÀ¹À¡£
Basically, the General Chapters of the European Pharmacopoeia will only be binding when they are referred to in a monograph; the only exception is when the reference made has only a recommendation character. This applies to all these five General Chapters. The purpose of the new text segment in the "Production" sections is to alert the applicant of a marketing authorisation of the risk related to such sulfonates impurities. He / she is not obliged to perform the analytical testing described in the general monographs; it is rather sufficient to strongly justify the absence of these impurities by means of a risk assessment in the application. The ultimate decision whether this justification is suffiicient lies with the assessor of the competent authority.
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

huama322

½ð³æ (СÓÐÃûÆø)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÄÄλ³æÓÑÓÐEP8.7ÖÐÕâÎå¸ö׍ָ·ÖÏíÒ»ÏÂ
8Â¥2016-06-01 08:51:00
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 8 ¸ö»Ø´ð

mouse103

ר¼Ò¹ËÎÊ (ÖøÃûдÊÖ)

ÄÄλ³æÓÑÓÐEP8.7ÖÐÕâÎå¸ö׍ָ·ÖÏíÒ»ÏÂ
3Â¥2016-05-05 10:09:03
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

kinggbp

ľ³æ (ÕýʽдÊÖ)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
¿ÆÑÐÐèÒª×öµÄ¹¤×÷Ì«¶àÁË¡¤¡¤¡¤¡¤¡¤¡¤¡¤
·ÂþÂþÆäÐÞÔ¶Ù⣬ÎÒ½«ÉÏ϶øÇóË÷£¡
5Â¥2016-05-06 15:13:29
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Ì«-Ñô-Óê

ľ³æ (ÕýʽдÊÖ)

Сľ³æ

»³×Ų»Í¬µÄÃÎÏ룬¹ý×ÅÏàËÆµÄÈËÉú
6Â¥2016-05-06 19:06:10
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 291 Çóµ÷¼Á +6 »¯¹¤2026½ì±ÏÒµÉ 2026-03-21 7/350 2026-03-26 02:14 by BruceLiu320
[¿¼ÑÐ] 316Çóµ÷¼Á +9 ÁºÜçö© 2026-03-19 9/450 2026-03-25 23:01 by peike
[¿¼ÑÐ] 308Çóµ÷¼Á +5 īīĮ 2026-03-25 5/250 2026-03-25 22:19 by 544594351
[¿¼ÑÐ] 26¿¼ÑÐ-291·Ö-ÏÃÃÅ´óѧ£¨085601£©-ÈáÐÔµç×ÓѧԺ²ÄÁϹ¤³ÌרҵÇóµ÷¼Á +3 min3 2026-03-24 4/200 2026-03-25 18:22 by xcjcqu
[¿¼ÑÐ] ²ÄÁÏѧ˶333Çóµ÷¼Á +4 ±±µÀÏï 2026-03-24 4/200 2026-03-25 14:16 by mapenggao
[¿¼ÑÐ] 347Çóµ÷¼Á +4 L when 2026-03-25 4/200 2026-03-25 13:37 by cocolv
[¿¼ÑÐ] Çóµ÷¼Á£¬Ò»Ö¾Ô¸:ÄϾ©º½¿Õº½Ìì´óѧ´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶£¬×Ü·Ö289·Ö +6 @taotao 2026-03-19 6/300 2026-03-25 08:37 by ľÍÐζ¶
[¿¼ÑÐ] Ò»Ö¾Ô¸±±»¯315 Çóµ÷¼Á +3 akrrain 2026-03-24 3/150 2026-03-24 19:35 by ÁËÁËÁËÁË¡£¡£
[¿¼ÑÐ] ²ÄÁÏ292µ÷¼Á +8 éÙËÌ˼ÃÀÈË 2026-03-23 8/400 2026-03-24 16:33 by laoshidan
[¿¼ÑÐ] 307Çóµ÷¼Á +5 ³¬¼¶ÒÁ°º´óÍõ 2026-03-24 5/250 2026-03-24 15:46 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] ¡¾Ë«Ò»Á÷ԺУÐÂÄÜÔ´¡¢»·¾³²ÄÁÏ£¬²ÄÁϼӹ¤ÓëÄ£ÄâÕÐÊÕ´óÁ¿µ÷¼Á¡¿ +4 Higraduate 2026-03-22 7/350 2026-03-24 11:23 by ÖÖ´óÊ÷
[¿¼ÑÐ] 291Çóµ÷¼Á +8 hhhhxn.. 2026-03-23 8/400 2026-03-23 23:15 by peike
[ÂÛÎÄͶ¸å] ¼±·¢ºËÐÄÆÚ¿¯ÂÛÎÄ +3 ÏÍ´ïÎʽò 2026-03-23 5/250 2026-03-23 17:13 by ÃÃ×Ó²»ºÃÈÇ
[¿¼ÑÐ] Ò»Ö¾Ô¸070300Õã´ó»¯Ñ§358·Ö£¬Çóµ÷¼Á£¡ +4 ËÖËÖÓã.. 2026-03-21 4/200 2026-03-23 08:12 by Iveryant
[¿¼ÑÐ] Çóµ÷¼ÁԺУÐÅÏ¢ +6 CX 330 2026-03-21 6/300 2026-03-22 15:25 by ÎÞи¿É»÷111
[¿¼ÑÐ] ÉúÎïѧµ÷¼Á +5 Surekei 2026-03-21 5/250 2026-03-22 14:39 by tcx007
[¿¼ÑÐ] 269ר˶Çóµ÷¼Á +6 ½ð¶÷±´ 2026-03-21 6/300 2026-03-22 14:31 by ColorlessPI
[¿¼ÑÐ] 296Çóµ÷¼Á +4 www_q 2026-03-20 4/200 2026-03-21 17:26 by ѧԱ8dgXkO
[¿¼ÑÐ] 329Çóµ÷¼Á +9 ÏëÉÏѧ߹߹ 2026-03-19 9/450 2026-03-20 22:01 by luoyongfeng
[¿¼ÑÐ] Çóµ÷¼Á +3 @taotao 2026-03-20 3/150 2026-03-20 19:35 by JourneyLucky
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û